First Manhattan’s UroGen Pharma URGN Stock Holding History

First Manhattan’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,500	Closed	-$22.5K	–	1286
2024 Q1	$22.5K	Hold	1,500	–	–	﹤0.01%	1015
2023 Q4	$22.5K	Buy	1,500 +500	+50%	+$6.49K	﹤0.01%	1010
2023 Q3	$14K	Hold	1,000	–	–	﹤0.01%	1078
2023 Q2	$10.3K	Hold	1,000	–	–	﹤0.01%	1136
2023 Q1	$9.24K	Hold	1,000	–	–	﹤0.01%	1223
2022 Q4	$8.87K	Hold	1,000	–	–	﹤0.01%	1269
2022 Q3	$8K	Hold	1,000	–	–	﹤0.01%	1248
2022 Q2	$8K	Hold	1,000	–	–	﹤0.01%	1273
2022 Q1	$8K	Hold	1,000	–	–	﹤0.01%	1323
2021 Q4	$9K	Hold	1,000	–	–	﹤0.01%	1306
2021 Q3	$16K	Hold	1,000	–	–	﹤0.01%	1200
2021 Q2	$15K	Hold	1,000	–	–	﹤0.01%	1212
2021 Q1	$19K	Hold	1,000	–	–	﹤0.01%	1141
2020 Q4	$18K	Hold	1,000	–	–	﹤0.01%	1075
2020 Q3	$19K	Hold	1,000	–	–	﹤0.01%	1034
2020 Q2	$26K	Hold	1,000	–	–	﹤0.01%	988
2020 Q1	$17K	Buy	1,000 +500	+100%	+$13.5K	﹤0.01%	1034
2019 Q4	$16K	Hold	500	–	–	﹤0.01%	1087
2019 Q3	$11K	Hold	500	–	–	﹤0.01%	1149
2019 Q2	$17K	Buy	+500	New	+$18.4K	﹤0.01%	1110

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

First Manhattan's URGN Position: Q2 2024 in Review

First Manhattan sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 1,500 shares — an estimated $22.5K sold.

First Manhattan first reported a position in URGN in Q2 2019 and held it in 20 quarters. The position peaked at $26K in Q2 2020. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

First Manhattan reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 1,500 UroGen Pharma shares in Q2 2024, an estimated $22.5K.
First Manhattan first reported a position in UroGen Pharma in Q2 2019 and held it in 20 quarters.
First Manhattan's UroGen Pharma position peaked at $26K in Q2 2020.
115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.